There are plenty of such confirmations on the Internet. Other Reta boosters also point to its alleged ability to reduce drug and alcohol cravings. (Some clinical publications suggest the potential of GLP-1 drugs in the treatment of addiction, attributed to their ability to reprogram dopamine signaling in the brain.) Less desirable side effects reported in studies and anecdotally include low energy levels, dizziness, hyperaesthesia (a form of extreme sensitivity to touch), and decreased libido.
Eli Lilly, the drug’s manufacturer, is currently completing Phase III trials. If all goes according to plan, FDA approval should follow and the drug could be launched in tardy 2026 or early 2027, based on the launch schedule of other drugs in this category. In a statement to WIRED, Lilly spokeswoman Niki Biro noted that due to its effectiveness, retatrutide is currently targeted at “people with a high BMI or obesity-related complications who require significant weight loss and may have a greater clinical need.”
Biro also warns that “retatrutide is an investigational molecule that is legally available only to Lilly clinical trial participants. Anyone purporting to sell retatrutide for human use is breaking the law, and no one should consider taking anything claiming to be retatrutide outside of a Lilly-sponsored clinical trial.” When WIRED brought this to Terry, he reiterated that these products are not intended for human consumption. “It’s for research purposes only,” he says. “Everything is available on the website.”
Suffice it to say that online sellers potentially risk infringing patents protected by pharmaceutical companies. Dresser says manufacturers of such chemicals can learn about a drug’s molecular structure by referring to patent literature submitted by pharmaceutical sponsors to regulatory agencies such as the FDA.
When reached for comment, the FDA pointed to previous warnings issued against companies selling retatrutide. “These products were sold directly to consumers for human use with dosing instructions,” the FDA said in a statement to WIRED. “The agency urges consumers not to purchase these products, the quality of which is unknown and may be harmful to their health.”
Pending FDA approval, the drug will likely find a flourishing market on the Internet, explored by users looking to speed up weight loss or speed reduction, and sold by middlemen such as Jake Terry. “The only reason I did it was to increase accessibility,” Terry says. “If I can help people become healthier, that’s my goal.”